COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2022 and 2021 is as follows (in thousands):

Year ended December 31, 2022	Contingent Consideration Liability Related to Acquisition of:
	Arkis  (See Note 4)				Location in Financial Statements	Derma Sciences		ACell Inc.  (See Note 4)				SIA				Location in Financial Statements
	Short-term		Long-term			Long-term		Short-term		Long-term		Long-term
Balance as of January 1, 2022	$	3,691	$	11,408		$	230	$	—	$	21,800	$	—
Additions	—		—			—				—		57,607
Transfers from long-term to current portion	—		—			—		4,885		(4,885)		—
Change in fair value of contingent consideration liabilities	(846)		(1,358)		Research and development	—		(4,885)		(13,215)		—				Selling, general and administrative
Balance as of December 31, 2022	$	2,845	$	10,050		$	230	$	—	$	3,700	$	57,607	$	—

Year ended December 31, 2021	Contingent Consideration Liability Related to Acquisition of:
	Arkis  (See Note 4)				Location in Financial Statements	Derma Sciences		ACell Inc.  (See Note 4)		Location in Financial Statements
	Short-term		Long-term			Long-term		Long-term
Balance as of January 1, 2021	$	3,415	$	11,746		$	230	$	—
Additions	—		—			—		23,900
Transfers from long-term to current portion	276		(276)			—		—
Change in fair value of contingent consideration liabilities	—		$	(62)	Research and development	—		(2,100)		Selling, general and administrative
Balance as of December 31, 2021	$	3,691	$	11,408		$	230	$	21,800